A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 64th largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 27th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 8 started in 2013.
This study's enrollment of 33 is close to the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 91st largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2013, is one of 62 in phase 3, and was the 32nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with Cystic Fibrosis (CF) who have a CFTR gating mutation in at least 1 allele and will further explore the efficacy of long-term ivacaftor treatment in this population of patients with CF.
Inclusion Criteria (Ivacaftor Arm):
Inclusion Criteria (Observational Arm):
Exclusion Criteria (Ivacaftor Arm):
Exclusion Criteria: (Observational Arm)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be: * 50 mg q12h for subjects 2 to \<6 years of age and \<14 kg, * 75 mg q12h for subjects 2 to \<6 years of age and ≥ 14 kg, or * 150 mg q12h for subjects ≥ 6 years of age.
Drug: Ivacaftor
Also known as: VX-770, Kalydeco
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent.
Time frame: Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)
Absolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
Time frame: Baseline (study 108), Week 24, 48, 72 and 84 (study 109)
Absolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of \>=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
Time frame: Baseline (study 109), Week 24, 48, 72 and 84 (study 109)
Absolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84
Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145)
Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Absolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84
Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Absolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Absolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Absolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
Time frame: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
Absolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
Time frame: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
This was a Phase 3, multicenter, 2 arm study in participants who received at least 1 dose of study drug in parent study VX11-770-108 (study 108) (NCT01705145).
| Milestone | Ivacaftor |
|---|---|
| Started | 33 |
| Completed | 28 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Continued with commercial kalydeco | 2 |
| Withdrew: Difficulty in swallowing | 1 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent.
| participants | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| AEs | 9 | 24 |
| SAEs | 6 | 5 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
| millimole per liter (mmol/L) | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n=7,22) | 93.1 ± 16.2 | 99.6 ± 13.6 |
| Absolute Change at Week 24 (n=6,18) | -62.1 ± 12.4 | -48.5 ± 18.4 |
| Absolute Change at Week 48 (n=6,15) | -29.3 ± 37.8 | -51.8 ± 27.1 |
| Absolute Change at Week 72 (n=7,14) | -46.4 ± 16.0 | -52.9 ± 26.7 |
| Absolute Change at Week 84 (n=6,14) | -46.5 ± 31.0 | -58.1 ± 23.9 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of \>=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
| mmol/L | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n= 8,23) | 47.8 ± 23.3 | 52.9 ± 23.1 |
| Absolute Change at Week 24 (n=7,18) | -4.3 ± 31.6 | 3.4 ± 15.9 |
| Absolute Change at Week 48 (n=7,17) | 18.1 ± 39.5 | -4.5 ± 22.6 |
| Absolute Change at Week 72 (n=8,15) | -1.5 ± 24.3 | -6.0 ± 20.8 |
| Absolute Change at Week 84 (n=7,16) | -2.4 ± 44.2 | -11.2 ± 25.4 |
Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145)
| kilogram (kg) | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n=9, 24) | 12.5 ± 1.1 | 16.8 ± 1.8 |
| Absolute Change at Week 12 (n= 9, 23) | 1.3 ± 0.4 | 1.9 ± 0.7 |
| Absolute Change at Week 24 (n=9, 23) | 2.0 ± 0.6 | 2.5 ± 0.9 |
| Absolute Change at Week 36 (n=9, 23) | 2.4 ± 0.7 | 3.1 ± 1.0 |
| Absolute Change at Week 48 (n=9, 22) | 2.6 ± 0.9 | 3.4 ± 1.1 |
| Absolute Change at Week 60 (n=9, 22) | 3.2 ± 1.0 | 4.0 ± 1.3 |
| Absolute Change at Week 72 (n=9, 20) | 3.4 ± 0.9 | 4.8 ± 1.6 |
| Absolute Change at Week 84 (n=9, 19) | 4.0 ± 1.2 | 5.7 ± 1.9 |
Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
| Kg | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n= 9, 24) | 13.5 ± 1.0 | 18.3 ± 2.0 |
| Absolute Change at Week 12 (n=9, 23) | 0.3 ± 0.4 | 0.4 ± 0.5 |
| Absolute Change at Week 24 (n=9, 23) | 1.0 ± 0.5 | 1.0 ± 0.7 |
| Absolute Change at Week 36 (n=9, 23) | 1.4 ± 0.6 | 1.6 ± 0.8 |
| Absolute Change at Week 48 (n=9, 22) | 1.6 ± 0.7 | 1.9 ± 0.8 |
| Absolute Change at Week 60 (n=9, 22) | 2.2 ± 0.8 | 2.5 ± 1.1 |
| Absolute Change at Week 72 (n=9, 20) | 2.4 ± 0.7 | 3.3 ± 1.4 |
| Absolute Change at Week 84 (n=9, 19) | 3.0 ± 1.0 | 4.2 ± 1.7 |
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
| Centimeters (cm) | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n=9, 24) | 89.1 ± 4.3 | 102.3 ± 6.4 |
| Absolute Change in Week 12 (n=9, 23) | 4.6 ± 1.2 | 5.4 ± 1.1 |
| Absolute Change in Week 24 (n=9, 23) | 6.0 ± 1.7 | 7.7 ± 3.3 |
| Absolute Change in Week 36 (n=9, 23) | 7.8 ± 1.8 | 8.8 ± 1.4 |
| Absolute Change in Week 48 (n=9, 21) | 9.7 ± 2.0 | 10.4 ± 1.7 |
| Absolute Change in Week 60 (n=9, 22) | 11.0 ± 2.2 | 11.6 ± 2.0 |
| Absolute Change in Week 72 (n=9, 20) | 12.5 ± 2.6 | 13.4 ± 2.0 |
| Absolute Change in Week 84 (n=9, 19) | 13.6 ± 2.3 | 15.0 ± 2.3 |
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
| cm | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n=9, 24) | 91.7 ± 4.3 | 105.8 ± 6.6 |
| Absolute Change at Week 12 (n=9, 23) | 2.0 ± 1.1 | 1.8 ± 0.9 |
| Absolute Change at Week 24 (n=9, 23) | 3.4 ± 1.2 | 4.1 ± 3.2 |
| Absolute Change at Week 36 (n=9, 23) | 5.2 ± 1.5 | 5.2 ± 1.1 |
| Absolute Change at Week 48 (n=9, 21) | 7.2 ± 1.3 | 6.8 ± 1.3 |
| Absolute Change at Week 60 (n=9, 22) | 8.4 ± 1.4 | 8.0 ± 1.5 |
| Absolute Change at Week 72 (n=9, 20) | 10.0 ± 2.1 | 9.8 ± 1.6 |
| Absolute Change at Week 84 (n=9, 19) | 11.1 ± 1.7 | 11.4 ± 1.9 |
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145).
| Kilogram per square meter (kg/m^2) | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n=9, 24) | 15.74 ± 0.69 | 16.06 ± 1.15 |
| Absolute Change at Week 12 (n=9, 23) | 0.03 ± 0.40 | 0.09 ± 0.60 |
| Absolute Change at Week 24 (n=9, 23) | 0.31 ± 0.57 | -0.12 ± 0.90 |
| Absolute Change at Week 36 (n=9, 23) | 0.15 ± 0.52 | 0.09 ± 0.73 |
| Absolute Change at Week 48 (n=9, 22) | -0.31 ± 0.60 | -0.13 ± 0.77 |
| Absolute Change at Week 60 (n=9, 22) | -0.12 ± 0.70 | -0.06 ± 0.90 |
| Absolute Change at Week 72 (n=9, 20) | -0.38 ± 0.68 | 0.09 ± 0.97 |
| Absolute Change at Week 84 (n=9, 19) | -0.16 ± 0.96 | 0.28 ± 0.97 |
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412).
| kg/m^2 | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Baseline (n= 9, 24) | 16.07 ± 0.55 | 16.33 ± 1.12 |
| Absolute Change at Week 12 (n= 9, 23) | -0.30 ± 0.60 | -0.16 ± 0.48 |
| Absolute Change at Week 24 (n= 9, 23) | -0.02 ± 0.70 | -0.36 ± 1.03 |
| Absolute Change at Week 36 (n= 9, 23) | -0.18 ± 0.83 | -0.16 ± 0.63 |
| Absolute Change at Week 48 (n= 9, 22) | -0.64 ± 0.81 | -0.35 ± 0.57 |
| Absolute Change at Week 60 (n= 9, 22) | -0.45 ± 0.82 | -0.29 ± 0.72 |
| Absolute Change at Week 72 (n= 9, 20) | -0.71 ± 0.90 | -0.21 ± 0.78 |
| Absolute Change at Week 84 (n= 9, 19) | -0.49 ± 1.09 | -0.01 ± 0.87 |
Collected over Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivacaftor 50 mg | — | 6/9 (66.7%) | 9/9 (100%) |
| Ivacaftor 75 mg | — | 5/24 (20.8%) | 24/24 (100%) |
| Event | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/9 | 3/24 |
| Alanine aminotransferase increasedInvestigations | 2/9 | 0/24 |
| Aspartate aminotransferase increasedInvestigations | 2/9 | 0/24 |
| PyrexiaGeneral disorders | 2/9 | 0/24 |
| Respiratory syncytial virus infectionInfections and infestations | 1/9 | 0/24 |
| Adenovirus test positiveInvestigations | 1/9 | 0/24 |
| DehydrationMetabolism and nutrition disorders | 1/9 | 0/24 |
| Enterovirus infectionInfections and infestations | 0/9 | 1/24 |
| Staphylococcal infectionInfections and infestations | 0/9 | 1/24 |
| Seizure anoxicNervous system disorders | 0/9 | 1/24 |
| Event | Ivacaftor 50 mg | Ivacaftor 75 mg |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 8/9 | 16/24 |
| PyrexiaGeneral disorders | 7/9 | 6/24 |
| VomitingGastrointestinal disorders | 6/9 | 7/24 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/9 | 3/24 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 4/9 | 2/24 |
| RashSkin and subcutaneous tissue disorders | 3/9 | 1/24 |
| Otitis mediaInfections and infestations | 2/9 | 4/24 |
| SinusitisInfections and infestations | 2/9 | 3/24 |
| RhinitisInfections and infestations | 2/9 | 1/24 |
| ConjunctivitisEye disorders | 2/9 | 0/24 |
| Age, Continuous(years) | Ivacaftor |
|---|---|
| Mean | 3.7 ± 1.04 |
| Gender(Participants) | Ivacaftor |
|---|---|
| Female | 6 |
| Male | 27 |
The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →